REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, $0.0001 par value (RVPH)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
RVPH on Nasdaq
Shares outstanding
120,538,577
Price per share
$0.68
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
9,455,573
Total reported value
$3,485,209
% of total 13F portfolios
0%
Share change
-6,581,318
Value change
-$2,522,742
Number of holders
38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, $0.0001 par value (RVPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC 9.9% $4,080,000 8,000,000 HIGHBRIDGE CAPITAL MANAGEMENT, LLC 30 Jun 2025
SAXENA PARAG 5.2% -17% $3,384,723 +$4,428 6,268,006 +0.13% Parag Saxena 18 Dec 2025
683 Capital Management, LLC 5.4% $2,771,850 5,435,000 683 CAPITAL MANAGEMENT, LLC 22 Sep 2025
Bhat Laxminarayan 3.8% -28% $1,877,246 +$34,930 3,680,874 +1.9% Bhat Laxminarayan 22 Sep 2025
CVI Investments, Inc. 4.9% -17% $1,821,518 -$218,482 3,571,603 -11% CVI Investments, Inc. 30 Jun 2025
TANG CAPITAL MANAGEMENT LLC 4.8% -38% $1,733,987 -$260,268 3,399,975 -13% TANG CAPITAL MANAGEMENT, LLC 30 Jun 2025
Schonfeld Strategic Advisors LLC 2.8% $762,651 1,314,915 Schonfeld Strategic Advisors LLC 31 Dec 2024
As of 30 Sep 2025, REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, $0.0001 par value (RVPH) has 38 institutional shareholders filing 13F forms. They hold 9,455,573 shares. of 120,538,577 outstanding shares (7.8%) .

Institutional Holders of REVIVA PHARMACEUTICALS HOLDINGS, INC. - Common Stock, $0.0001 par value (RVPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 0 $0 -$4,000 $0.68 0
2025 Q3 9,455,573 $3,485,209 -$2,522,742 $0.37 38
2025 Q2 14,276,867 $5,439,564 +$2,030,905 $0.38 44
2025 Q1 7,316,794 $6,939,218 -$2,147,979 $0.95 47
2024 Q4 7,732,309 $14,008,817 -$4,024,379 $1.81 42
2024 Q3 9,947,227 $14,936,260 +$4,666,858 $1.44 33
2024 Q2 6,849,687 $8,748,871 +$1,342,403 $1.28 32
2024 Q1 5,573,837 $21,010,997 -$1,864,526 $3.78 30
2023 Q4 10,378 $53,447 $5.15 1
2023 Q3 2,663,385 $13,004,016 -$556,557 $4.88 24
2023 Q2 2,636,201 $15,447,187 +$8,416,332 $5.86 22
2023 Q1 1,375,662 $5,761,612 +$298,177 $4.19 22
2022 Q4 1,303,532 $5,539,575 +$2,023,623 $4.25 24
2022 Q3 865,615 $1,376,000 -$905,811 $1.59 15
2022 Q2 1,865,547 $2,053,000 -$114,800 $1.10 11
2022 Q1 1,901,522 $4,677,000 -$2,055,762 $2.46 14
2021 Q4 2,612,910 $7,543,000 -$15,648 $2.89 11
2021 Q3 2,603,081 $10,549,000 -$229,541 $4.06 11
2021 Q2 2,652,392 $12,779,000 +$9,606,651 $4.86 11
2021 Q1 586,328 $3,365,000 +$1,292,852 $5.74 7
2020 Q4 360,070 $3,149,000 +$3,149,011 $8.77 3